The DOI matches its Crossref record; 43 of the 47 references it cites were found in a registry or an index.
Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial
Open accessAbstract
Importance: As men age, they experience decreased serum testosterone concentrations, decreased bone mineral density (BMD), and increased risk of fracture. Objective: To determine whether testosterone treatment of older men with low testosterone increases volumetric BMD (vBMD) and estimated bone strength. Design, Setting, and Participants: Placebo-controlled, double-blind trial with treatment allocation by minimization at 9 US academic medical centers of men 65 years or older with 2 testosterone concentrations averaging less than 275 ng/L participating in the Testosterone Trials from December 2011 to June 2014. The analysis was a modified intent-to-treat comparison of treatment groups by multivariable linear regression adjusted for balancing factors as required by minimization. Interventions: Testosterone gel, adjusted to maintain the testosterone level within the normal range for young men, or placebo gel for 1 year. Main Outcomes and Measures: Spine and hip vBMD was determined by quantitative computed tomography at baseline and 12 months. Bone strength was estimated by finite element analysis of quantitative computed tomography data. Areal BMD was assessed by dual energy x-ray absorptiometry at baseline and 12 months. Results: There were 211 participants (mean [SD] age, 72.3 [5.9] years; 86% white; mean [SD] body mass index, 31.2 [3.4]). Testosterone treatment was associated with significantly greater increases than placebo in mean spine trabecular vBMD (7.5%; 95% CI, 4.8% to 10.3% vs 0.8%; 95% CI, -1.9% to 3.4%; treatment effect, 6.8%; 95% CI, 4.8%-8.7%; P < .001), spine peripheral vBMD, hip trabecular and peripheral vBMD, and mean estimated strength of spine trabecular bone (10.8%; 95% CI, 7.4% to 14.3% vs 2.4%; 95% CI, -1.0% to 5.7%; treatment effect, 8.5%; 95% CI, 6.0%-10.9%; P < .001), spine peripheral bone, and hip trabecular and peripheral bone. The estimated strength increases were greater in trabecular than peripheral bone and greater in the spine than hip. Testosterone treatment increased spine areal BMD but less than vBMD. Conclusions and Relevance: Testosterone treatment for 1 year of older men with low testosterone significantly increased vBMD and estimated bone strength, more in trabecular than peripheral bone and more in the spine than hip. A larger, longer trial could determine whether this treatment also reduces fracture risk. Trial Registration: clinicaltrials.gov Identifier: NCT00799617.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These trials and other independent studies found that T administration in elderly men resulted in improvements in sexual function,202, 203 lean body mass,204, 205 physical function,206 strength,25, 205, 207 protein synthesis,25 cholesterol,204, 205, 208 and bone density.209”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [209]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760 · cited 2×
“Decrease in Testosterone as Men Age As men age, their serum testosterone concentration falls gradually from age 20 to over age 80, as demonstrated by both cross-sectional (1) and longitudinal studies (2-4).”
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Effect of testosterone and estradiol in a man with aromatase deficiency
Carani, C., Qin, K., Simoni, M., Faustini-Fustini, M., Serpente, S., Boyd, J., Korach, K. S., & Simpson, E. R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707103370204 · Cited by 1,151
Wu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939
Minimization: A new method of assigning patients to treatment and control groups
Taves, D. R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974155443 · Cited by 891
Effects of Testosterone Treatment in Older Men
Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506119 · Cited by 890
Self-citationKatznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757
Flagged first, then by citations
4 of the 47 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–361 of 361
Nieschlag, E., & Behre, H. M. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-61904-9_36-1
Benefits and Risks of Testosterone Replacement in the Older Man with Hypogonadism
Marcelli, M., & Mediwala, S. N. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_30
Casos clínicos en osteoporosis
Martínez, W. A. R., & Castaño, P. (2023) · Interdisciplinary Journal of Epidemiology and Public Health · doi:10.18041/2665-427x/ijeph.2.9881
Osteoporosis Prevention and Treatment
Humphrey, M. B., Zahedi, B., Warriner, A. H., Morgan, S., Leder, B. Z., Saag, K. G., & Yu, E. W.-Y. (2023) · Springer eBooks · doi:10.1007/978-3-031-23488-0_41
Solaković, S., Solaković, N., Jogunčić, A., Spahović, H., Hajrulahović, F., Pavlović, R., Vrcić, M., Solaković, E., Godinjak, A., Skrypchenko, I. T., et al. (2023) · Zaporozhye Medical Journal · doi:10.14739/2310-1210.2023.2.268513
“Therefore, we need longer studies including more patients with intramuscular synthetic testosterone therapy (different types of esters) to develop new treatment guidelines for cardiovascular pathology and generalized atherosclerosis [5,39,43,48,54].”
BackgroundTestosterone Replacement Therapy for Treatment of Osteoporosis in Men
Elsheikh, A., & Rothman, M. S. (2023) · Faculty Reviews · doi:10.12703/r/12-18 · Cited by 1
Male Hypogonadism and Aging: An Update
Iglesias, P., Núñez, A., & Díez, J. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_9
Cardiovascular safety of testosterone replacement therapy
Čapka, D. (2023) · Urologie pro praxi · doi:10.36290/uro.2023.070
Systemic Sclerosis - Recent Advances and New Perspectives
Lakota, K., Pirkmajer, K. P., & Burja, B. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.102205
Important Considerations for Bone Health Management in Systemic Sclerosis Patients
Frech, M. E., Adeogun, G., Chew, E. Y., Frech, T., & Tanner, S. B. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1001825
Pros and cons of hormone replacement therapy
Zinoviev, A. A., & Валерьевна, Л. А. (2023) · Scientific Bulletin of the Omsk State Medical University · doi:10.61634/2782-3024-2023-9-59-70
Testosterone Treatment and Fractures in Men with Hypogonadism
Kovac, E., Weiss, R. E., & Arap, W. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2401934
Ushimaru, S., Sumi, H., Aso, M., Fujishima, R., Shiizaki, K., & Tominaga, N. (2024) · JCEM Case Reports · doi:10.1210/jcemcr/luae055
“Nonetheless, a 1-year randomized controlled study demonstrated that testosterone increased the volumetric BMD of the trabecular bone in the spine site in contrast to a placebo (4).”
BackgroundTestosteron – der Einfluss eines Sexualhormons auf den männlichen Körper
Jäger, T. (2024) · Springer eBooks · doi:10.1007/978-3-662-68405-4_1
Role of estrogens and androgens in osteoporosis
Laurent, M. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00041-8
Hypogonadism and testosterone therapy in elderly men
Yeap, B. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00046-7
Wang, C., Nguyen, B. T., & Swerdloff, R. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00091-1
Self-citationMännlicher Hypogonadismus und Alterung: ein Update
Iglesias, P., Núñez, A., & Díez, J. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_9
Reproductive and nonreproductive actions of testosterone
Gagliano‐Jucá, T., Jain, A., Jasuja, R., & Bhasin, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00198-9
Self-citationManagement of Osteoporosis in the Orthopedic Trauma Patient
Chou, S. H.-H. (2025) · Springer eBooks · doi:10.1007/978-3-031-80825-8_8
Hormone replacement therapy, male
Wang, C., & Swerdloff, R. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00263-6
Self-citationAndrogen Receptor Ligands: Agonists and Antagonists
Orafidiya, F. A., Monaghan, A. E., & McEwan, I. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21477-6.00453-3
Testosterone Therapy in Men with Functional Hypogonadism
Mauvais‐Jarvis, F. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_15
History of Testosterone Therapy in Men with Testosterone Deficiency: 1939–2024
Traish, A. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_14
Testosterone Treatment of Late-Onset Hypogonadism: Benefits and Risks
Snyder, P. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_28
Self-citationTestosterone Replacement Therapy
Amory, J. K., & Amory, T. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_18
Leydig Cell Function in Obesity and Diabetes
Grossmann, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_34
Testosterone Measurement, Use and Misuse
Handelsman, D. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_17
Vincentis, S. D., David, K., Antonio, L., & Rochira, V. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_22
Trejo, P., & Martínez, C. (2025) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2025.07.002
Methadone Maintenance Treatment, Sex Hormones, and Bone Mineral Density in Persons Who Inject Drugs
Wehbeh, L., Hsu, H.-Y., Dias, J. P., Moseley, K. F., Langan, S. J., Jiang, Y., Piggott, D. A., Kirk, G. D., Dobs, A. S., Brown, T. T., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf140
“…with a mediation effect of sex hormones on the relationship between methadone maintenance therapy and BMD, we observed that free T and E2 explained most of methadone’s effect at the LS, which is composed mostly of trabecular bone and is more susceptible to changes in the hormonal environment [40].”
Riscos e efeitos do uso abusivo de esteroides anabolizantes androgênicos entre jovens e adultos
da Silva, G. A., Mendonça, R. D. L., dos Santos, C. M. S., Viana, R. F. A., Carvalho, A. B., & da Silva, W. L. (2025) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv17n11-037
Khatri, K., Gupta, N., Aggarwal, S., Lakhani, A., Dahuja, A., Kankaria, A., & Kanwal, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29025-1.00017-5
Lima, L. C. D., Cavalcante, I. R., Rocha, F. E. O., Jorge, J. O., Martins, T., Madeira, M. F. M., Campagnole‐Santos, M. J., Macari, S., Nascentes, C. C., Nunes, E. H. M., et al. (2026) · Calcified Tissue International · doi:10.1007/s00223-025-01465-8
Osteoporosis in men: what changed?
Tomková, S., & Vrsko, M. (2019) · Clinical Osteology · doi:10.36290/clo.2019.016
Musculoskeletal and metabolic effects of androgen deprivation therapy in men with prostate cancer
Radev, S., Siderova, M. V., & Dimitrova, Y. (2026) · Scripta Scientifica Medica · doi:10.14748/sr9y5s28
“…is largely reversible upon discontinuation of therapy [41] In the T-Trials: Bone Trial, 12 months of testosterone gel therapy increased BMD and an estimated bone strength index compared with placebo, as assessed by DXA and high-resolution peripheral quantitative computed tomography (HR-pQCT) [42].”
Gadallah, A. I., Abdelhaffez, A., Hussein, O. A., Sayed, S. A., Abdelhakiem, M. A. H., & El-Mottaleb, N. A. A. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0063
Testosterone replacement therapy in older men: skeletal outcomes and fracture risk
Szarpak, P. L., Al-Jeabory, M., Pecold, J., & Maslyk, M. M. (2026) · The Aging Male · doi:10.1080/13685538.2026.2655544 · Cited by 1
Newman, M. S., Smeaton, J., Gillson, G., & Jaferi, A. (2026) · Frontiers in Reproductive Health · doi:10.3389/frph.2026.1804311
“…a group of seven coordinated placebo-controlled trials showed that transdermal TRT for 1 year in hypogonadal men significantly increased volumetric bone mineral density and estimated bone strength, without greater incidence of prostate or cardiovascular adverse events compared to placebo (15).”
InfluentialChiu, Y. C., & Shen, Y. C. (2026) · Frontiers in Sports and Active Living · doi:10.3389/fspor.2026.1648181
Bone Metabolism and Testicular Dysfunction
Graziani, A., Grande, G., & Ferlin, A. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_51-1
Smadi, Z., Pereira, D. E., Mozny, A., Irfan, B., Boutros, M., & Hosseinzadeh, P. (2026) · Injury · doi:10.1016/j.injury.2026.113445
Stump, K., Aynaszyan, S., Totis, F., Pazionis, T. J. C., & Passias, P. G. (2026) · Spine Open · doi:10.1097/bn9.0000000000000121
From local to systemic: Spinal aging in the multi-organ aging network
Zhang, C., 彭舒畅, Fu, J., Du, Y., Qian, Y., Song, Y., Wang, K. J., & Yang, C. G. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103253
Bone health in aging men: it’s not just about testosterone
Filho, N. M., Ros, L. U. D., da Ros, J. P. U., Carvalhal, G. F., Hallak, J., & Ros, C. T. D. (2026) · The Journal of Sexual Medicine · doi:10.1093/jsxmed/qdag220
Hatta, S., Eguchi, Y., TAMURA, T., Sakamoto, S., Miyako, S., Toyoguchi, T., Shin, H., Kobayashi, T., Abe, Y., Saito, S., et al. (2026) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2026.06.015
Clinical advances and technical challenges of quantitative computed tomography
Walle, M., Matheson, B. E., & Boyd, S. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26739-0.00015-6
Associations of Serum Testosterone and 25-Hydroxyvitamin D with Bone Mineral Density in Aging Men
Bae, W. J., Kim, S.-M., Lee, H. J., Huh, W., & Lee, D. S. (2026) · The World Journal of Men s Health · doi:10.5534/wjmh.260018
Self-citationFarzam, K. (2026) · Cureus · doi:10.7759/cureus.114876
“In the Bone Trial of the Testosterone Trials, one year of testosterone gel increased spine volumetric bone density and estimated bone strength compared with placebo [42].”
Han, W., Stump, K., Gubara, K., Gottipati, P., Aynaszyan, S., & Pazionis, T. J. C. (2026) · Global Spine Journal · doi:10.1177/21925682261487188
Hypogonadism in aging men: Impact of comorbidities, diagnosis and treatment
Ravelli, S. A., Maseroli, E., & Vignozzi, L. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109124
Key findings on the efficacy and safety of testosterone therapy from two large randomized trials
Braga, M., & Basaria, S. S. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag397
Self-citationTHE BIOCHEMISTRY OF TESTOSTERONE: A REVIEW AND SYNTHESIS OF CURRENT SCIENTIFIC EVIDENCE
Бондарева, А. В., Yemelianenko, E. R., & Stetsenko, S. O. (2026) · Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії · doi:10.31718/2077-1096.26.3.307
Flamman, W. R., Trueba-Timmermans, D. J., Grootjen, L. N., de Graaff, L. C. G., Geelen, J. M., van der Velden, J. A. E. M., Rings, E. H. H. M., Hokken-Koelega, A., & Kerkhof, G. F. (2026) · Clinical Endocrinology · doi:10.1111/cen.70213
Chen, A. M., Garg, R., & Swerdloff, R. S. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2026.08.014
Self-citationRutter, M. M., Crane, J. L., Babalola, F., Benjamin, R. W., Lam, C., McAdam, L. C., Nicolau, S., Sbrocchi, A. M., Scavina, M. T., Sorbara, J., et al. (2026) · Journal of Neuromuscular Diseases · doi:10.1177/22143602261486896
Update on testosterone deficiency and therapeutic options for testosterone replacement therapy
Thompson, T., Mubarak, M., Jones, T. H., Pearce, I., & Modgil, V. (2026) · Nature Reviews Urology · doi:10.1038/s41585-026-01190-3
Kruger, R. E., Yohannes, H., Cho, E., Eisner, L. E., Pfau, D. R., Chan‐Sui, R. K., Migotsky, N., da Rocha, A. M., Killian, M. L., Moravek, M. B., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1940100
Air pollution and bone fractures in a high-risk population: differences by age and sex
Dahl, C., Madsen, C., Omsland, T. K., Frohn, L. M., Geels, C., Holvik, K., & Meyer, H. E. (2026) · Environment International · doi:10.1016/j.envint.2026.110570
Zitzmann, M., Bosnyák, Z., Jones, R. L., & Caliber, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71384
Testosterone, Testosterone Replacement Therapy, and Cardiovascular Disease: A Contemporary Review
Maligireddy, A. R., Barua, S. T., & Barua, R. S. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.054307
Metadata
- Authors
- Snyder, P. J., Kopperdahl, D. L., Stephens-Shields, A. J., Ellenberg, S. S., Cauley, J. A., Ensrud, K. E., Lewis, C. E., Barrett-Connor, E., Schwartz, A. V., Lee, D. C., Bhasin, S., Cunningham, G. R., Gill, T. M., Matsumoto, A. M., Swerdloff, R. S., Basaria, S., Diem, S. J., Wang, C., Hou, X., Cifelli, D., Dougar, D., Zeldow, B., Bauer, D. C., & Keaveny, T. M.
- Affiliations
- University of Pennsylvania (US)
- O.N. Diagnostics (United States) (US)
- Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
- University of Pittsburgh (US)
- University of Minnesota (US)
- University of Alabama at Birmingham (US)
- University of California San Diego (US)
- University of California, San Francisco (US)
- Brigham and Women's Hospital (US)
- Baylor College of Medicine (US)
- Yale University (US)
- University of Washington (US)
- University of California, Los Angeles (US)
- University of California, Berkeley (US)
- Corresponding author
- Snyder, Peter J.
- ORCID
- Snyder, Peter J.
- Kopperdahl, David L.
- Ellenberg, Susan S.
- Cauley, Jane A.
- Ensrud, Kristine E.
- Lewis, Cora E.
- Barrett-Connor, Elizabeth
- Schwartz, Ann V.
- Lee, David C.
- Bhasin, Shalender
- Cunningham, Glenn R.
- Gill, Thomas M.
- Matsumoto, Alvin M.
- Swerdloff, Ronald S.
- Basaria, Shehzad
- Diem, Susan J.
- Wang, Christina
- Hou, Xiaoling
- Zeldow, Bret
- Bauer, Douglas C.
- Keaveny, Tony M.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2017-04-01
- Volume
- 177
- Issue
- 4
- Pages
- 471
- ISSN
- 2168-6106 (ISSN-L)
- PMC
- PMC5433755
- OpenAlex
- W2591696989
- Cited by
- 363
- References
- 47
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 37 · 2023: 37 · 2022: 41 · 2021: 44 · 2020: 30 · 2019: 34 · 2018: 32 · 2017: 22
- FWCI
- 25.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (5p60dk079626-05, UL1TR000142, 5p30ag031679-15, UL1TR001863)
- National Institute on Aging (U01AG030644, R01AG037679, K07AG043587, P30-AG031679, P30AG021342)
- National Institute of Diabetes and Digestive and Kidney Diseases (P60-DK-079626, P30DK079626)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, androgen deficiency, hypogonadism, older men, volumetric bone mineral density, bone strength, trabecular bone, hip bone, spine bone, testosterone gel, finite element analysis, fracture risk, bone mineral density, hormone replacement therapy, osteoporosis prevention
- MeSH terms
- Aged, Androgens, Double-Blind Method, Drug Administration Routes, Hip Fractures, Humans, Lumbar Vertebrae, Male, Testosterone, Tomography, X-Ray Computed, Absorptiometry, Photon, Bone Density, Spinal Fractures, Treatment Outcome, Drug Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
